Lawsuit Filed on Behalf of New Jersey Man Alleges Actos Caused Bladder Cancer

Share Article

Parker Waichman LLP has filed a lawsuit alleging that Actos (pioglitazone) caused bladder cancer in a New Jersey man. The Type 2 diabetes medication is associated with an increased risk of bladder cancer, most recently in a study published in the Journal of the National Cancer Institute.

News Image

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a man who alleges that taking Actos caused his bladder cancer. The suit was filed on September 17th in the U.S. District Court for the Western District of Louisiana (Case No. 6:12-cv-2491) as part of the multidistrict litigation known as In Re: Actos (Pioglitazone) Products Liability Litigation (M DL No. 6:11-md-2299). Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos in 2004 and developed bladder cancer in 2006. The lawsuit alleges that the cancer was a direct result of using Actos, and caused the Plaintiff to suffer severe mental and physical pain and suffering, permanent injuries and emotional distress, economic loss due to medical expenses and living related expenses due to a new lifestyle. The suit also alleges loss of consortium on behalf of his spouse.

Allegedly, the Defendants failed to adequately inform consumers about the increased risk of bladder cancer while taking Actos. In particular, the suit emphasizes the increased risk observed after one year of use; the U.S Food and Drug Administration (FDA) added this information to the drug’s warning label last July.

Actos was approved in 1999 to treat Type 2 diabetes. It is part of the thiazolidinedione drug class, which also includes the drug Avandia. In August, the Journal of the National Cancer Institute published a study showing an increased risk of bladder cancer with the long-term use of Actos and other TZDs. The month prior, the Canadian Medical Association Journal found that using Actos was associated with a 22 percent increased risk of bladder cancer. The research was based on data from 10 studies and over 2.6 million patients.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz, Managing Attorney
Follow us on
Visit website